Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Tax Provisions (2021 - 2025)

Apellis Pharmaceuticals has reported Tax Provisions over the past 5 years, most recently at $313000.0 for Q4 2025.

  • Quarterly results put Tax Provisions at $313000.0 for Q4 2025, up 19.47% from a year ago — trailing twelve months through Dec 2025 was $1.7 million (up 52.12% YoY), and the annual figure for FY2025 was $1.7 million, up 48.19%.
  • Tax Provisions for Q4 2025 was $313000.0 at Apellis Pharmaceuticals, down from $602000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for APLS hit a ceiling of $1.4 million in Q4 2023 and a floor of -$1.5 million in Q4 2022.
  • Median Tax Provisions over the past 5 years was $341000.0 (2025), compared with a mean of $353000.0.
  • Biggest five-year swings in Tax Provisions: tumbled 517.9% in 2022 and later skyrocketed 366.0% in 2025.
  • Apellis Pharmaceuticals' Tax Provisions stood at $352000.0 in 2021, then tumbled by 517.9% to -$1.5 million in 2022, then surged by 197.35% to $1.4 million in 2023, then crashed by 81.7% to $262000.0 in 2024, then rose by 19.47% to $313000.0 in 2025.
  • The last three reported values for Tax Provisions were $313000.0 (Q4 2025), $602000.0 (Q3 2025), and $466000.0 (Q2 2025) per Business Quant data.